ABSTRACT
Brexanolone,also known as 3a,5a-tetrahydroprogesterone ,is a metabolite of progesterone and an important neuroactive steroid with a wide range of biological activities.Recently,the most exciting thing is that 2019 year the FDA has approved its treatment of postpartum depression ,which is also the only drug to obtain indications for postpartum depression.It is expected to officially enter the market by the end of June 2019 year.This article reviews the research progress of its pharmacological action.
ABSTRACT
Brexanolone, also known as 3a, 5a-tetrahydroprogesterone, is a metabolite of progesterone and an important neuroactive steroid with a wide range of biological activities.Recently, the most exciting thing is that 2019 year the FDA has approved its treatment of postpartum depression, which is also the only drug to obtain indications for postpartum depression.It is expected to officially enter the market by the end of June 2019 year.This article reviews the research progress of its pharmacological action.